MedTrace Logo

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

NCT05757102 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2025-10-07

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Conditions

Interventions

DRUG

FF/UMEC/VI

FF/UMEC/VI will be administered.

DEVICE

ELLIPTA

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

DRUG

FF/VI

FF/VI will be administered.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2027-01-15
Completion
2027-01-15
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Chile
  • New Zealand
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05757102 on ClinicalTrials.gov